target audience: TECH BUYER Publication date: Sep 2023 - Document type: IDC Perspective - Doc Document number: # US51207023
How TechBios and Biotechs Are Leveraging Generative AI to Transform Drug Discovery
Content
List of Figures
Get More
When you purchase this document, the purchase price can be applied to the cost of an annual subscription, giving you access to more research for your investment.
Related Links
Abstract
This IDC Perspective discusses the growing importance of generative AI in powering drug discovery. It evaluates the significant potential of this opportunity, touches upon the challenges and complexities associated with the same, and highlights various generative AI approaches that have been implemented to discover new drugs. It maps the industry landscape, identifies key players involved, and provides guidance to the technology buyer on the implementation of this technology.
"The world of innovative TechBios and biotechs is exploding and will continue to grow exponentially. This will be followed by mergers and acquisitions. 'Design as a service' leveraging generative AI will serve to accelerate drug discovery and scale precision medicine strategy. These are still early days for the use of generative AI in drug discovery, and there will be hiccups and pushbacks. Navigating an evolving regulatory landscape and ensuring the trustworthiness of the models will be a daunting task. Yet the fire has been lit and generative AI will blaze a trail in the path for drug discovery. What was once mere science fiction is rapidly becoming a reality," said Dr. Nimita Limaye, research VP, Life Sciences R&D Strategy and Technology at IDC.